
50% Upside For MRVL Stock?
CHONGQING, CHINA - MARCH 3: In this photo illustration, the Marvell Technology Inc. logo is ... More displayed on a smartphone screen on March 3, 2025, in Chongqing, China. (Photo by)
Marvell Technology (NASDAQ:MRVL), a firm focused on manufacturing semiconductor integrated circuits for data centers, has recently revealed its Q1 fiscal 2026 results. The company slightly surpassed analyst predictions, disclosing earnings of $0.62 per share on revenues of $1.9 billion, compared to consensus estimates of $0.61 and $1.88 billion, respectively. In spite of this positive outcome, Marvell's stock fell by 3% in after-hours trading and has declined by 43% since the start of the year. A considerable part of this downturn took place in March, following a disappointing outlook. Investors looking for steady returns may want to consider investigating diversified investment options such as the Trefis High Quality portfolio, which has shown remarkable performance, achieving over 91% returns since its inception. Additionally, see – Nvidia Stock's 1 Big Risk
Considering the stock's fluctuations and the recent decline, you might be questioning whether Marvell is currently a good buy. From a valuation perspective, MRVL stock seems appealing. At approximately $62 per share, it is trading at 8.3 times trailing revenues and 32 times trailing adjusted earnings. This is significantly lower than its three-year average price-to-sales (P/S) ratio of 10.4 times and price-to-earnings (P/E) ratio of 42 times.
While a decrease in valuation multiples may appear justified given the company's average revenue growth of only 10% over the last three years and a shrinkage in its adjusted net income margin from 30.5% in fiscal 2023 to 26.3% currently, this does not convey the complete picture.
Marvell's Q1 results demonstrated impressive growth, with overall revenues soaring by 63% year-over-year. This was fueled by a strong 76% rise in core data center sales, reaching $1.44 billion. This increase is largely due to the rising demand for custom AI chips. Although the adjusted gross margin decreased by 240 basis points year-over-year to 59.8%, the company's bottom line witnessed a substantial enhancement, reporting earnings of $0.62 per share, marking a 158% increase from $0.24 in the same quarter last year. In the future, Marvell expects Q2 sales to be around $2.0 billion, which aligns with market expectations.
Building upon the valuation discussion, Marvell is currently experiencing growth at a much quicker rate than it has over the past three years. Analysts estimate that sales are projected to grow by 42% this year and an additional 20% next year. This accelerated growth trajectory is anticipated to have an even greater influence on earnings, which are expected to rise by 2.3 times during this period. This swift growth trend calls for an upward adjustment in valuation multiples. Notably, the average analyst price target of $96 for MRVL indicates a considerable upside potential of more than 50%.
Marvell's strategic foray into the AI sector began with its interconnect solutions for data centers. However, the greater opportunity lies in the creation of application-specific integrated circuits (ASICs), which function as custom AI chips. These tailored chips for hyperscaler data centers offer numerous benefits over general-purpose GPUs, such as those provided by Nvidia and AMD. Specialized chips can lower costs, enhance energy efficiency, and optimize performance for specific functionalities, unlike general-purpose GPUs intended for a wider range of applications. Marvell has been strengthening its alliances with significant AI stakeholders, including Amazon Web Services, which has expanded its agreements for data center semiconductors, including bespoke AI products.
While the valuation of MRVL stock seems enticing, it is essential to take potential risks into account. Historically, Marvell's stock has underperformed in comparison to the broader market during economic downturns. For example, during the inflation shock of 2022, it fell by 62% from its peak, in contrast to a 25.4% decline for the S&P 500. Similarly, amid the COVID-19 pandemic correction in 2020, it dropped by 40% versus a 33.9% decrease for the S&P 500. This trend indicates that MRVL stock is more vulnerable to negative macroeconomic conditions.
In addition, there are ongoing concerns regarding the slow rollout of Amazon's Trainium chips amid weak external demand, which could potentially hinder future revenue growth. Therefore, while Marvell stock might seem attractive from a valuation angle, investors should carefully assess these risks.
You may want to purchase MRVL during this current dip, but investing in a single stock, regardless of its potential, carries risks. If you aim to mitigate that risk while still positioning yourself for strong upside, consider the High Quality portfolio, which has surpassed the S&P 500 and achieved returns exceeding 91% since its launch. Why is that? As a collective, HQ Portfolio stocks have offered superior returns with lower risk compared to the benchmark index; presenting a smoother ride, as evidenced in HQ Portfolio performance metrics.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Forbes
24 minutes ago
- Forbes
AI Talent Pipeline: How Nations Compete In The Global AI Race
The artificial intelligence revolution is often framed as a clash of algorithms and infrastructure, but its true battleground lies in the minds shaping it – the AI talent. While nations vie for technological supremacy, the real contest revolves around human capital-who educates, retains, and ethically deploys the brightest minds. This deeper struggle, unfolding across universities, immigration offices, and corporate labs, beneath the surface of flashy model releases and geopolitical posturing, will determine whether AI becomes a force for equitable progress or a catalyst for deeper global divides. China's educational machinery is producing graduates at an unprecedented scale. In 2024, approximately 11.79 million students graduated from Chinese universities, an increase of 210,000 from the previous year, with around 1.6 million specializing in engineering and technology in 2022. By comparison, the United States produces far fewer graduates (around 4.1 million overall in 2022), with only 112,000 graduating with computer and information science degrees. This numerical advantage is reshaping the global talent landscape. According to MacroPolo's Global AI Talent Tracker, China has expanded its domestic AI talent pool significantly, with the percentage of the world's top AI researchers originating from China (based on undergraduate degrees) rising from 29% in 2019 to 47% in 2022. However, the United States remains "the top destination for top-tier AI talent to work," hosting approximately 60% of top AI institutions. Despite this, America's approach to talent faces structural challenges. The H-1B visa cap, which limits skilled foreign workers, is 'set at 65,000 per fiscal year, with an additional 20,000 visas for those with advanced U.S. degrees'. This constraint affects the tech industry's ability to recruit globally. This self-imposed constraint forces companies like Google and Microsoft to establish research centers in Toronto and London – a technological offshoring driven not by cost but by talent access. Europe's predicament completes this global triangle of talent misallocation. The continent invests heavily in AI education – ETH Zurich and Oxford produce world-class specialists-only to watch a significant number board one-way flights to California, lured by higher salaries and cutting-edge projects. This exodus potentially creates a vicious cycle: fewer AI experts means fewer competitive startups, which means fewer reasons for graduates to stay – a continental brain drain that undermines Europe's digital sovereignty. As AI permeates daily life, a quieter conflict emerges: balancing innovation with ethical guardrails. Europe's GDPR has levied huge fines since 2018 for data misuse, such as the $1.3 billion imposed on Meta for transferring EU citizens' data to the US without adequate safeguards, while China's surveillance networks track citizens through 626 million CCTV cameras. U.S. giant Apple was recently fined $95 million amid claims they were spying on users over a decade-long period. These divergent approaches reflect fundamentally different visions for AI's role in society. 'AI is a tool, and its values are human values. That means we need to be responsible developers as well as governors of this technology-which requires a framework,' argues Fei-Fei Li, Stanford AI pioneer. Her call for ethical ecosystems contrasts sharply with China's state-driven model, where AI development aligns with national objectives like social stability and economic planning. The growing capabilities of AI raise significant questions about the future of work. Andrew Ng, co-founder of Google Brain, observes: 'AI software will be in direct competition with a lot of people for a lot of jobs.' McKinsey estimates that 30% of U.S. jobs could be automated by 2030, but impacts will vary wildly. According to the WEF Future of Jobs Report 2025, 'on average, workers can expect that two-fifths (39%) of their existing skill sets will be transformed or become outdated over the 2025-2030 period.' The report goes on to state that, 'the fastest declining roles include various clerical roles, such as cashiers and ticket clerks, alongside administrative assistants and executive secretaries, printing workers, and accountants and auditors.' These changes are accelerated by AI and information processing technologies, as well as an increase in digital access for businesses. The panic that could be caused by these figures is palpable, but some are arguing that the real challenge isn't job loss – it's ensuring that displaced workers can transition to new roles. Countries investing in vocational AI training, like Germany's Industry 4.0 initiative, could potentially achieve smoother workforce transitions. By 2030, China could reverse its brain drain through initiatives like the Thousand Talents Plan, which has already repatriated over 8,000 scientists since 2008. If successful, this repatriation could supercharge domestic innovation while depriving Western labs of critical expertise. Europe's stringent AI Act may inadvertently cede ground to less regulated regions. Businesses could potentially start self-censoring AI projects to avoid EU compliance costs, with complexity, risk governance, data governance and talent listed as the 4 major challenges facing EU organisations in light of this Act, according to McKinsey. They went further to state that only 4% of their survey respondents thought that the requirements of the EU AI Act were even clear. This could create an innovation vacuum, pushing experimental AI development to jurisdictions with less stringent oversight. Breakthroughs in quantum computing could reshape talent flows. IBM's Condor and China's Jiuzhang 3.0 are vying to crack quantum supremacy, with the winner likely attracting a new wave of specialists. 'We need to make the world quantum-ready today by focusing on education and workforce development,' according to Alessandro Curioni, vice-president at IBM Research Europe. A recent WEF report on quantum technologies warns that, 'demand for experts is outpacing available talent and companies are struggling to recruit people in this increasingly competitive and strategic industry.' An IBM quantum data center dpa/picture alliance via Getty Images The focus on human talent suggests a more nuanced understanding of AI development – one that values creative problem-solving and ethical considerations alongside technical progress. "I think the future of global competition is, unambiguously, about creative talent," explains Vivienne Ming, executive chair and co-founder of Socos Labs. 'Everyone will have access to amazing AI. Your vendor on that will not be a huge differentiator. Your creative talent though-that will be who you are.' Similarly, Silvio Savarese, executive vice president and chief scientist at Salesforce AI Research, believes: 'AI is placing tools of unprecedented power, flexibility and even personalisation into everyone's hands, requiring little more than natural language to operate. They'll assist us in many parts of our lives, taking on the role of superpowered collaborators.' The employment landscape for AI talent faces complex challenges. In China, the record graduating class of 11.8 million students in 2024 confronts a difficult job market, with youth unemployment in urban areas at 18.8% in August, the highest for the year. These economic realities are forcing both countries to reconsider how they develop, attract, and retain AI talent. The competition isn't just about who can produce or attract the most talent – it's about who can create environments where that talent can thrive and innovate responsibly. The AI race transcends technical capabilities and infrastructure. While computing power, algorithms, and data remain important, human creativity, ethics, and talent ultimately determine how AI will shape our future. As nations compete for AI dominance, they must recognize that sustainable success requires nurturing not just technical expertise but also creative problem-solving and ethical judgment – skills that remain distinctly human even as AI capabilities expand. In this regard success isn't about which nation develops the smartest algorithms, but which creates environments where human AI talent can flourish alongside increasingly powerful AI systems. This human element may well be the deciding factor in who leads the next phase of the AI revolution.
Yahoo
44 minutes ago
- Yahoo
Toyota's 2026 Camry: Now With 100% More Sass and Attitude
Toyota's bringing the Nightshade trim to the 2026 Camry, and it's more than just a style play. It's still hybrid-only, which means top-tier fuel economy without sacrificing punch. This ninth-gen Camry shows up with sharp new looks and performance tweaks that go beyond surface level. It's got a revamped powertrain, electric all-wheel drive, and those stealthy blacked-out Nightshade vibes. This isn't the Camry you remember from family road trips. Whether you're chasing efficiency, edge, or a solid daily driver, the 2026 Camry might catch you off guard—in a good way. Toyota's best-selling sedan is turning up the attitude for 2026 with the new Camry Nightshade Edition. This stealthy, aggressive trim joins the ninth-generation lineup with a fresh dose of edge. Built on Toyota's all-hybrid Camry platform, the Nightshade stands out with blacked-out details, 19-inch black alloy wheels, and Midnight Black Metallic accents everywhere from the grille to the diffuser. It comes in three bold color options: Ice Cap, Supersonic Red, and Midnight Black Metallic—each pairing eye-catching design with hybrid efficiency. Under the hood, every 2026 Camry gets Toyota's fifth-gen hybrid system, combining a 2.5-liter 4-cylinder engine with an electric motor. It delivers 225 horsepower in front-wheel drive and 232 in all-wheel drive. Toyota has tweaked the setup for smoother, more natural acceleration. Plus, a recalibrated e-CVT improves throttle response while keeping fuel economy sky-high—up to 51 mpg combined in the FWD LE model. For extra traction and peace of mind, Electronic On-Demand AWD is now available on all five Camry trims—LE, SE, XLE, XSE, and Nightshade. Instead of a mechanical driveshaft, it uses a rear-mounted electric motor, making the system lighter, quicker to respond, and 30 horsepower stronger than before. Whether you're navigating slick roads or winding backroads, the AWD setup helps deliver better grip, stability, and sharper steering. It's smart enough to send torque where it's needed, exactly when it's needed. Design-wise, the 2026 Camry gets a serious glow-up. Created by CALTY Design Studios in California and Michigan, the new look includes a bold hammerhead front fascia, standard LED lighting, and a lower, more streamlined stance. Each trim brings its own flair with unique grille and wheel designs. The SE and XSE trims go sportier with mesh grilles, dual exhaust tips, aerodynamic accents, and blacked-out details—plus, the XSE adds a slick two-tone option with a black roof and bold colors like Supersonic Red and the new Dark Cosmos. Inside, each Camry trim brings its own vibe—from the LE's clean, minimalist layout to the XLE's more premium feel with upscale materials. Sportier models like the SE and XSE add flair with contrast stitching, paddle shifters, and supportive bolstered seats. Across the board, the 2026 Camry is packed with standard tech and safety features. Toyota's newest infotainment system comes with an 8-inch screen or an optional 12.3-inch upgrade for those who want a bit more. We already love what Toyota did with the 2025 Prius Nightshade, and the Camry seems ready to follow suit. The full 2026 Camry lineup, including the sleek Nightshade Edition, lands in dealerships fall 2025—with pricing to be revealed closer to launch. With bold styling, improved hybrid power, and optional all-wheel drive, this is the most capable Camry yet. And for those craving something with a little more attitude, the Nightshade might just be the one to watch. Source: Toyota, HotCars
Yahoo
44 minutes ago
- Yahoo
Avistone Announces Encouraging Results for Vebreltinib plus Andamertinib (PLB1004) in EGFR-mutated NSCLC with MET Amplification or Overexpression at ASCO Annual Meeting 2025
BEIJING, May 31, 2025--(BUSINESS WIRE)--Beijing Avistone Biotechnology Co., Ltd ("Avistone"), an innovative biotechnology company focused on precision oncology therapeutics, today announced that the clinical data for Vebreltinib plus Andamertinib (PLB1004), its innovative combination of potent mesenchymal-epithelial transition factor (MET) inhibitor and epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), has been presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2025. The details of the poster presentation are provided below: Poster title: Vebreltinib plus Andamertinib (PLB1004) in EGFR-mutated NSCLC with MET Amplification or Overexpression after failure on EGFR-TKIs treatment: phase Ib/II KYLIN-1 studyAbstract Number For Publication: 8632Session: Poster Session-Lung Cancer- Non-Small Cell MetastaticLocation: Poster Board, 112Session Date/Time: 5/31/2025 1:30pm-4:30pm CDT MET amplification or overexpression is the most common "off-target" mechanism that drives resistance to EGFR-TKIs in NSCLC patients. The results from Phase Ib/II KYLIN-1 study (NCT06343064) showed that Vebreltinib plus Andamertinib demonstrated notable efficacy and manageable safety in EGFR-mutated NSCLC patients with MET amplification or overexpression after EGFR-TKIs failure. Among the 56 patients enrolled at a dose of Vebreltinib 150mg BID plus Andamertinib 80mg QD (RP2D), the confirmed overall response rate (ORR) was 50.0%, and the median progression-free survival (mPFS) was 9.9 months. In 19 patients with brain metastases, ORR was 42.1% and mPFS was 9.5 months. Grade 3 or higher treatment related adverse events (TRAEs) occurred in 19.6% of the patients. None discontinued treatment or died due to TRAEs. No new safety signal was observed. A multicenter Phase III study, KYLIN-3 study (NCT06970782), is currently ongoing to further evaluate Vebreltinib plus Andamertinib versus platinum-based doublet chemotherapy in patients with EGFR mutations, MET amplification and/or overexpression, locally advanced or metastatic NSCLC following EGFR-TKI failure. To obtain a copy of the poster, please email Avistone. About Vebreltinib Vebreltinib is an orally, potent and selective c-Met inhibitor. Chinese National Medical Products Administration (NMPA) has formally approved the use of Vebreltinib in locally advanced or metastatic NSCLC patients with MET exon 14 skipping mutations, as well as adult patients with isocitrate dehydrogenase mutant astrocytoma with the PTPRZ1-MET fusion gene or glioblastoma with a history of low-grade disease who have the PTPRZ1-MET fusion gene and have failed previous treatments. Currently, Chinese Center for Drug Evaluation (CDE) has formally accepted its New Drug Application (NDA) and granted it priority review, intended for patients with locally advanced or metastatic NSCLC with MET amplification. About Andamertinib (PLB1004) Andamertinib (PLB1004) is an oral, potent, irreversible, and selective EGFR-TKI with potent blood-brain barrier penetration and broad tyrosine kinase activity. Preclinical studies have shown that it can effectively and irreversibly target exon 20 insertion. Additionally, it can also potently target classical EGFR mutations, such as Del19, L858R and T790M with a high degree of selectivity. About Avistone Biotechnology Beijing Avistone Biotechnology Co., Ltd. ("Avistone") is an innovative biotechnology company dedicated to precision therapies with significant unmet medical needs for patients worldwide. Avistone maintains an extensive pipeline of targeted therapies in Non-Small Cell Lung Cancer (NSCLC) and other solid tumors. View source version on Contacts BD@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data